CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 162 enrolled
Drug / intervention
Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension +1 moredrug
Likely dose
Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspensionAI-extracted
Key inclusion· 3
  • ✓Diagnosis of open-angle glaucoma or ocular hypertension
  • ✓Able to attend all study visits and be housed overnight at clinical site for study assessments
  • ✓Willing and able to sign informed consent form
Key exclusion· 3
  • ✕Pregnant, breastfeeding, or planning pregnancy without adequate birth control
  • ✕Glaucoma type other than open-angle glaucoma or ocular hypertension
  • ✕Best-corrected visual acuity less than 55 ETDRS letters (approximately 20/80 Snellen) in either eye

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02770248
NCT02770248Phase 4Completed
CompareCT.gov

24-hr Intraocular Pressure Control With Brinzolamide 1% / Brimonidine 0.2% Ophthalmic Suspension vs Vehicle

Alcon Research·interventional·Posted May 12, 2016·Updated Jul 2, 2018

In Brief

A Phase 4 clinical trial evaluating Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension and Vehicle for Glaucoma. Completed, enrolled 162 participants.

Detailed Summary

The purpose of this study is to evaluate differences between treatments in mean change from baseline in 24-hr intraocular pressure (IOP) at Week 4.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 12, 2016
Enrollment StartMay 23, 2016
Primary CompletionJan 14, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 10.1 years ago

Interventions

Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspensiondrug

Vehicledrug

Inactive ingredients used as a placebo for masking purposes